153 related articles for article (PubMed ID: 37839597)
1. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies.
Thapa R; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Saleem S; Khan R; Altwaijry N; Dureja H; Singh SK; Dua K
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127375. PubMed ID: 37839597
[TBL] [Abstract][Full Text] [Related]
2. Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases.
Zhu Y; Wang H; Guo Y; Cao J; Li H
Mini Rev Med Chem; 2023; 23(19):1893-1904. PubMed ID: 37055897
[TBL] [Abstract][Full Text] [Related]
3. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
Wagman AS; Johnson KW; Bussiere DE
Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.
Kotliarova S; Pastorino S; Kovell LC; Kotliarov Y; Song H; Zhang W; Bailey R; Maric D; Zenklusen JC; Lee J; Fine HA
Cancer Res; 2008 Aug; 68(16):6643-51. PubMed ID: 18701488
[TBL] [Abstract][Full Text] [Related]
6. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network.
Hermida MA; Dinesh Kumar J; Leslie NR
Adv Biol Regul; 2017 Aug; 65():5-15. PubMed ID: 28712664
[TBL] [Abstract][Full Text] [Related]
7. Glycogen synthase kinase 3: more than a namesake.
Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A
Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350
[TBL] [Abstract][Full Text] [Related]
8. The involvement of AMPK/GSK3-beta signals in the control of metastasis and proliferation in hepato-carcinoma cells treated with anthocyanins extracted from Korea wild berry Meoru.
Park SY; Lee YK; Lee WS; Park OJ; Kim YM
BMC Complement Altern Med; 2014 Mar; 14():109. PubMed ID: 24666969
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase (GSK) 3 in pregnancy and parturition: a systematic review of literature.
Lavu N; Richardson L; Bonney E; Menon R
J Matern Fetal Neonatal Med; 2020 Jun; 33(11):1946-1957. PubMed ID: 30278798
[No Abstract] [Full Text] [Related]
10. Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1).
Kim JW; Lee JE; Kim MJ; Cho EG; Cho SG; Choi EJ
J Biol Chem; 2003 Apr; 278(16):13995-4001. PubMed ID: 12584189
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-kinase and glycogen synthase kinase 3 regulate estrogen receptor-mediated transcription in neuronal cells.
Mendez P; Garcia-Segura LM
Endocrinology; 2006 Jun; 147(6):3027-39. PubMed ID: 16497810
[TBL] [Abstract][Full Text] [Related]
12. GSK-3 as a novel prognostic indicator in leukemia.
Ruvolo PP
Adv Biol Regul; 2017 Aug; 65():26-35. PubMed ID: 28499784
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
14. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review.
Glibo M; Serman A; Karin-Kujundzic V; Bekavac Vlatkovic I; Miskovic B; Vranic S; Serman L
Bosn J Basic Med Sci; 2021 Feb; 21(1):5-18. PubMed ID: 32767962
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.
Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ
ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.
Marchand B; Arsenault D; Raymond-Fleury A; Boisvert FM; Boucher MJ
J Biol Chem; 2015 Feb; 290(9):5592-605. PubMed ID: 25561726
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases.
Wang L; Li J; Di LJ
Med Res Rev; 2022 Mar; 42(2):946-982. PubMed ID: 34729791
[TBL] [Abstract][Full Text] [Related]
18. Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response.
Wang H; Brown J; Gu Z; Garcia CA; Liang R; Alard P; Beurel E; Jope RS; Greenway T; Martin M
J Immunol; 2011 May; 186(9):5217-26. PubMed ID: 21422248
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
Sugden PH; Fuller SJ; Weiss SC; Clerk A
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S137-53. PubMed ID: 18204489
[TBL] [Abstract][Full Text] [Related]
20. Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor.
Pilot-Storck F; Chopin E; Rual JF; Baudot A; Dobrokhotov P; Robinson-Rechavi M; Brun C; Cusick ME; Hill DE; Schaeffer L; Vidal M; Goillot E
Mol Cell Proteomics; 2010 Jul; 9(7):1578-93. PubMed ID: 20368287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
